DiFiore Emma, Pittman Julie
Anne Burnett Marion School of Medicine Texas Christian University, Fort Worth, TX, USA.
Case Rep Psychiatry. 2024 Jul 4;2024:8824770. doi: 10.1155/2024/8824770. eCollection 2024.
Phenibut, a GABA receptor agonist, has surged in popularity due to its nootropic and anxiolytic effects. Despite not being FDA approved, it is accessible online due to its marketing as a dietary supplement, leading to unregulated distribution. Increasing reports have highlighted the risks of addiction and severe withdrawal symptoms associated with phenibut use. This case report explores the management of phenibut withdrawal in an outpatient setting using a baclofen taper. The slow taper was complicated by various withdrawal symptoms, and the patient was ultimately stabilized on lorazepam, baclofen, gabapentin, and clonidine after 5-months time. This case is unique, as it also highlights challenges in tapering off baclofen following phenibut detoxification. The study underscores the need for further research on the pharmacological management of phenibut withdrawal, emphasizing the importance of raising awareness about phenibut's dangers and associated clinical presentations.
苯乙胺，一种GABA受体激动剂，因其益智和抗焦虑作用而广受欢迎。尽管未获美国食品药品监督管理局（FDA）批准，但由于其作为膳食补充剂进行销售，可在网上获取，导致其分销不受监管。越来越多的报告强调了与使用苯乙胺相关的成瘾风险和严重戒断症状。本病例报告探讨了在门诊环境中使用巴氯芬逐渐减量法管理苯乙胺戒断的情况。缓慢减量过程因各种戒断症状而变得复杂，患者最终在5个月后通过劳拉西泮、巴氯芬、加巴喷丁和可乐定实现了病情稳定。该病例具有独特性，因为它还凸显了苯乙胺解毒后逐渐停用巴氯芬时所面临的挑战。该研究强调了对苯乙胺戒断的药物管理进行进一步研究的必要性，强调了提高对苯乙胺危险性及相关临床表现认识的重要性。
